Urolog. pro Praxi, 2010; 11(5): 262-265

Active surveillance for low-risk prostate cancer - current view

MUDr.Ladislav Mašek, MUDr.Lubomír Hyršl
Urologické oddělení Oblastní nemocnice Kladno

The therapy of localized prostate cancer consists of several modalities. Besides radical prostatectomy and radiotherapy, active surveillance

(AS) of strictly selected patiens with low-risk disease is discussed. Candidates for AS are patiens with stable PSA level below 10 ng/mL,

with GS not more than 6 and low volume carcinoma of clinical stage T1 to T2a. In these patiens, where no or very slow progression is

assumed, AS is a good alternative to primary radical treatment. On the other hand there is a risk of prostate biopsy undergrading, which

could result in disease progression. In this review, we summarize current possibilities of this modality and its use in daily practice.

Keywords: prostate cancer, active surveillance, delayed therapy

Published: October 22, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Mašek L, Hyršl L. Active surveillance for low-risk prostate cancer - current view. Urol. praxi. 2010;11(5):262-265.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Databáze Globocan 2002. Dostupná na WWW: http://www-dep.iarc.fr/.
    2. Yin M, Bastacky S, Chandran U, et al. Prevalence of incidental prostate cancer in the general population: A study of healthy organ donors. J Urol 2008; 179: 892-895. Go to original source... Go to PubMed...
    3. Ries LA, Melbert D, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2005. Dostupná na WWW: http://seer.cancer.gov/csr/1975-2005/.
    4. Stephenson AJ, Klein EA, Kattan MW, et al. Predicting the long-term risk of prostate cancer specific mortality after radical prostatectomy. J Clin Oncol 2009; 27(15S): 236 s. Go to original source... Go to PubMed...
    5. Thaxton CS, Loeb S, Roehl KA, Kan D, Catalona WJ. Treatment outcomes of radical prostatectomy in potential candidates for 3 published aktive surveillance protocols. Urology. 2010; 75(2): 414-418. Roub 2008 Dec 5. Go to original source... Go to PubMed...
    6. Berglund RK, Masterson RA, Vora KC, et al. Pathological upgrading and upstaging with immediate repeat biopsy in patients eligible for active surveillance. J Urol 2008; 180: 1964-1968. Go to original source... Go to PubMed...
    7. Sheridan TB, Carter BH, Wang W, et al. Change in prostate cancer grade over time in men followed expectantly for stage T1c disease. J Urol 2008; 179: 901-905. Go to original source... Go to PubMed...
    8. Mufarrij P, Sankin A, Godoy G, Lepor H. Pathologic Outcomes of Candidates for Aktive Surveillance Undergoing Radical Prostatectomy. Urology. 2010 May 20. (Epub ahead of print). Go to original source... Go to PubMed...
    9. Bill-Axelson A, Holmberg L, Filen F, et al. Radical prostatectomy versus watchful waiting in localized prostate cancer: The Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst 2008; 100: 1154-1164. Go to original source... Go to PubMed...
    10. Roemeling S, Roobol MJ, de Vries SH, et al. Active surveillance for prostate cancers detected in 3 subsequent rounds of a screening trial: characteristics, PSA doubling times, and outcome. Eur Urol 2007; 51: 1244-1250; discussion, 1251. Go to original source... Go to PubMed...
    11. Klotz L. Active surveillance with selective delayed intervention for favorable risk prostate cancer. Urol Oncol 2006; 24: 46-50. Go to original source... Go to PubMed...
    12. Hardie C, Parker C, Norman A, et al. Early outcomes of active surveillance for localized prostate cancer. BJU Int. 2005; 95: 956-996. Go to original source... Go to PubMed...
    13. Van den Bergh RCN, Roemling S, Roobol MJ, et al. Outcomes of men with screen-detected prostate cancer eligilble for active surveillance who were managed expectantly. Eur Urol 2009; 55: 1-8. Go to original source... Go to PubMed...
    14. Klotz L. Active Surveillance for favorable risk prostate cancer: What are the results, and how safe is it? Semin in Rad Oncol 2008; 18: 2-6. Go to original source... Go to PubMed...
    15. Freedland SJ, Kane CJ, Amling, et al. Delay of radical prostatectomy and the risk of biochemical progression in men with low risk prostate cancer. J Urol 2006; 175: 1298-1302. Go to original source... Go to PubMed...
    16. Carter HB, Walsh PC, Landis P, Epstein JI. Expectant management of nonpalpable prostate cancer with curative intent: preliminary results. J Urol 2002; 167: 1231-1234. Go to original source... Go to PubMed...
    17. Patel MI, DeConcini DT, Lopez-Corona E, Ohori M, Wheeler T, Scardino PT. An analysis of men with clinically localized prostate cancer who deferred definitive therapy. J Urol 2004; 171: 1520-1524. Go to original source... Go to PubMed...
    18. Meng MV, Elkin EP, Harlan SR, Mehta SS, Lubeck DP, Carroll PR. Predictors of treatment after initial surveillance in men with prostate cancer: results from CaPSURE. J Urol 2003; 170(6 pt 1): 2279-2283. Go to original source... Go to PubMed...
    19. Zietman AL, Thakral H, Wilson L, Schellhammer P. Conservative management of prostate cancer in the prostate specific antigen era: the incidence and time course of subsequent therapy. J Urol 2001; 166: 1702-1706. Go to original source... Go to PubMed...
    20. Eggener SE, Mueller A, Berglund RK, et al. A multi-institutional evaluation of active surveillance for low risk prostate cancer, J Urol 2009; 181: 1635-1641. Go to original source... Go to PubMed...

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.